Ligand Pharmaceuticals Inc, LGND, FDA Calendar, PDUFA Date

Company Name	Ligand Pharmaceuticals Inc LGND
Drug Name	FILSPARI (sNDA)
Event Name	FDA decision on FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS)
Event Date	04/13/2026
Outcome Date
Outcome	Pending
Drug Status	FILSPARI is developed by Travere in collaboration with Ligand Pharma
Rival Drugs	If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure
Market Potential
Other Approvals	FILSPARI is already approved by the FDA to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.
News

Return to FDA Calendar

RELATED NEWS (Ligand Pharmaceuticals Inc)

Slide Shows